The global bioanalytical testing services market was worth USD 2.7 billion in 2020 and is further projected to reach USD 6.1 billion by 2027, at a CAGR of 12.1% during the forecast period (2021-2027).

Single-use technology manufacturing can attain cost-of-goods that are comparable to stainless-steel systems, noted WuXi.

WuXi Biologics (stock code: 2269) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover ...

Dr. Chris Chen, CEO of WuXi Biologics, commented ... the company has applied SUT manufacturing in over 300 batches of scaled production ranging from 4,000L to 16,000L across multiple facilities ...

Dr. Chris Chen, CEO of WuXi Biologics, commented, "The successful completion of ... Over the past six years, by leveraging continuous process innovation, the company has applied SUT manufacturing in ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dublin, April 15, 2025 (GLOBE NEWSWIRE) -- The "MRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis ...

IntroductionThe Global Plasmid DNA Manufacturing Market is poised for significant growth, with a valuation of USD 2.13 ...